Chiome Bioscience Inc.

Chiome Bioscience Inc. engages in the research and development of antibody drugs in Japan, Singapore, and internationally. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib system, a monoclonal antibody production technology that uses chicken immune cells to produce antibodies for drug discovery research. It also develops drugs under Phase I clinical trial, including ADCT-701, a humanized anti-dlk1 antibody for the treatment of solid tumors; CBA-1205, a humanized afucosylated anti-dlk1 antibody for the treatment of liver cancer, lung cancer, and neuroblastoma; and CBA-1535, a humanized anti 5T4xCD3 antibody for the treatment of malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and triple negative breast cancer. In addition, the company engages in the development of drugs under preclinical study, such as PCDC, a humanized anti- CDCP1 antibody for the treatment of lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, a humanized antibody 5T4/CD3/PD-L1 for the treatment of malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and triple negative breast cancer; BMAA, a humanized anti-semphorin3a antibody for the treatment of renal and other diseases; LIV-2008/2008b, a humanized anti-TROP-2 antibody for the treatment of breast, lung, and colorectal cancer; PFKR, a humanized anti-CX3CR1 antibody for the treatment of secondary progressive multiple sclerosis; and PXLR, a humanized anti-CXCL1/2/3/5 antibody for the treatment of gastric, breast, and ovarian tumors. Further, it provides protein expression and purification services; stable expression cell line creation; and antibody generation. The company was incorporated in 2005 and is headquartered in Shibuya, Japan.